The Human Hookworm Vaccine Initiative (HHVI) has identified and produced several candidates for potential use as a vaccine. Currently, two lead candidate antigens are being developed to stimulate the human immune system to produce antibodies that inhibit parasite blood feeding. Phase 1 clinical testing of the Na-GST-1 hookworm vaccine, began in January 2012. Currently clinical trials are being carried out in Minas Gerais, Brazil and Washington, DC.
The development of a successful vaccine is a significant undertaking that takes years to achieve. The Sabin Vaccine Institute Product Development Partnership (PDP) is internationally recognized for its development of safe, effective vaccines against tropical infections including human hookworm, schistosomiasis, Chagas disease, leishmaniasis and SARS. Sabin PDP esteemed partners include:
With over a decade of experience, Sabin PDP has produced a well-rounded model that serves as a blueprint for the development of safe and effective vaccines against vaccine preventable and neglected tropical diseases. Existing capabilities include:
Product Development: Established the infrastructure to engage in antigen discovery, rapid development of scalable manufacturing processes (process development), quality control, preclinical and clinical immunology and stability testing.
Most people have never heard of diseases like elephantiasis, river blindness, snail fever, trachoma, roundworm, whipworm, or hookworm. But one in six people globally, including more than half a billion children, have these organisms living and breeding inside their bodies.
Yet the solution to these diseases is relatively simple: For only 50 cents, we can provide one person with treatment and protection against all seven NTDs for up to one year.
Neglected tropical diseases (NTDs) are a group of 17 parasitic and bacterial infections that infect more than one billion people around the world, most of whom live on less than $1.25 per day. Without treatment, NTDs can lead to malnutrition, blindness, severe physical disabilities and even death.
The Global Network focuses our efforts on the seven most common NTDs, which make up 90 percent of the global NTD burden.
The Sabin Vaccine Institute PDP works on developing vaccines for the more than 700 million people suffering from hookworm in the world today. Established in 2000 with funding from the Bill & Melinda Gates Foundation, the Sabin PDP (originally the Human Hookworm Vaccine Initiative) is the first and only PDP in the world developing a vaccine for human hookworm infection.
Last Friday, Sabin president Dr. Peter Hotez was a featured guest on Soledad O’Brien’s CNN morning show “Starting Point.” On the show, Dr. Hotez discussed the burden of neglected tropical diseases (NTDs) globally and closer to home in the United States.
June 12, 2012
At the Sabin Vaccine Institute, advocacy is big part of our business. We encourage politicians, philanthropists and the general public to expand immunization programs for vaccine-preventable diseases and increase treatment for over one billion people suffering from neglected tropical diseases.
But we’re also one of the few NGOs that is leading the research and development of vaccines to prevent diseases of poverty.